Literature DB >> 31462075

Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation.

Wen Tian1,2, Xinguo Jiang1,2, Yon K Sung1,2, Eric Shuffle1,2, Ting-Hsuan Wu2, Peter N Kao2, Allen B Tu1,2, Peter Dorfmüller3,4,5, Aiqin Cao2, Lingli Wang2, Gongyong Peng1,2,6, Yesl Kim1,2, Patrick Zhang1,2, James Chappell2, Shravani Pasupneti1,2, Petra Dahms1,2, Peter Maguire2, Hassan Chaib2, Roham Zamanian2, Marc Peters-Golden7, Michael P Snyder2, Norbert F Voelkel8, Marc Humbert3,4,9, Marlene Rabinovitch2, Mark R Nicolls1,2.   

Abstract

BACKGROUND: Bmpr2 (bone morphogenetic protein receptor 2) mutations are critical risk factors for hereditary pulmonary arterial hypertension (PAH) with approximately 20% of carriers developing disease. There is an unmet medical need to understand how environmental factors, such as inflammation, render Bmpr2 mutants susceptible to PAH. Overexpressing 5-LO (5-lipoxygenase) provokes lung inflammation and transient PAH in Bmpr2+/- mice. Accordingly, 5-LO and its metabolite, leukotriene B4, are candidates for the second hit. The purpose of this study was to determine how 5-LO-mediated pulmonary inflammation synergized with phenotypically silent Bmpr2 defects to elicit significant pulmonary vascular disease in rats.
METHODS: Monoallelic Bmpr2 mutant rats were generated and found phenotypically normal for up to 1 year of observation. To evaluate whether a second hit would elicit disease, animals were exposed to 5-LO-expressing adenovirus, monocrotaline, SU5416, SU5416 with chronic hypoxia, or chronic hypoxia alone. Bmpr2-mutant hereditary PAH patient samples were assessed for neointimal 5-LO expression. Pulmonary artery endothelial cells with impaired BMPR2 signaling were exposed to increased 5-LO-mediated inflammation and were assessed for phenotypic and transcriptomic changes.
RESULTS: Lung inflammation, induced by intratracheal delivery of 5-LO-expressing adenovirus, elicited severe PAH with intimal remodeling in Bmpr2+/- rats but not in their wild-type littermates. Neointimal lesions in the diseased Bmpr2+/- rats gained endogenous 5-LO expression associated with elevated leukotriene B4 biosynthesis. Bmpr2-mutant hereditary PAH patients similarly expressed 5-LO in the neointimal cells. In vitro, BMPR2 deficiency, compounded by 5-LO-mediated inflammation, generated apoptosis-resistant and proliferative pulmonary artery endothelial cells with mesenchymal characteristics. These transformed cells expressed nuclear envelope-localized 5-LO consistent with induced leukotriene B4 production, as well as a transcriptomic signature similar to clinical disease, including upregulated nuclear factor Kappa B subunit (NF-κB), interleukin-6, and transforming growth factor beta (TGF-β) signaling pathways. The reversal of PAH and vasculopathy in Bmpr2 mutants by TGF-β antagonism suggests that TGF-β is critical for neointimal transformation.
CONCLUSIONS: In a new 2-hit model of disease, lung inflammation induced severe PAH pathology in Bmpr2+/- rats. Endothelial transformation required the activation of canonical and noncanonical TGF-β signaling pathways and was characterized by 5-LO nuclear envelope translocation with enhanced leukotriene B4 production. This study offers an explanation of how an environmental injury unleashes the destructive potential of an otherwise silent genetic mutation.

Entities:  

Keywords:  bmpr2 receptor; endothelial cells; inflammation; lung

Year:  2019        PMID: 31462075      PMCID: PMC6803052          DOI: 10.1161/CIRCULATIONAHA.119.040629

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  48 in total

1.  Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension.

Authors:  Krystyna Teichert-Kuliszewska; Michael J B Kutryk; Michael A Kuliszewski; Golnaz Karoubi; David W Courtman; Liana Zucco; John Granton; Duncan J Stewart
Journal:  Circ Res       Date:  2005-12-15       Impact factor: 17.367

Review 2.  Leukotrienes.

Authors:  Marc Peters-Golden; William R Henderson
Journal:  N Engl J Med       Date:  2007-11-01       Impact factor: 91.245

3.  Endothelial fate mapping in mice with pulmonary hypertension.

Authors:  Lina Qiao; Toshihiko Nishimura; Lingfang Shi; Dane Sessions; Ama Thrasher; James R Trudell; Gerald J Berry; Ronald G Pearl; Peter N Kao
Journal:  Circulation       Date:  2013-11-07       Impact factor: 29.690

Review 4.  Regulatory T cells and pulmonary hypertension.

Authors:  Rasa Tamosiuniene; Mark R Nicolls
Journal:  Trends Cardiovasc Med       Date:  2011-08       Impact factor: 6.677

5.  The coding sequence mediates induction of 5-lipoxygenase expression by Smads3/4.

Authors:  Sabine Seuter; Bernd L Sorg; Dieter Steinhilber
Journal:  Biochem Biophys Res Commun       Date:  2006-08-10       Impact factor: 3.575

6.  Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension.

Authors:  Rajkumar Savai; Hamza M Al-Tamari; Daniel Sedding; Baktybek Kojonazarov; Christian Muecke; Rebecca Teske; Mario R Capecchi; Norbert Weissmann; Friedrich Grimminger; Werner Seeger; Ralph Theo Schermuly; Soni Savai Pullamsetti
Journal:  Nat Med       Date:  2014-10-26       Impact factor: 53.440

7.  Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension.

Authors:  Frédéric Perros; Peter Dorfmüller; David Montani; Hamida Hammad; Wim Waelput; Barbara Girerd; Nicolas Raymond; Olaf Mercier; Sacha Mussot; Sylvia Cohen-Kaminsky; Marc Humbert; Bart N Lambrecht
Journal:  Am J Respir Crit Care Med       Date:  2011-11-22       Impact factor: 21.405

8.  5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension.

Authors:  L Wright; R M Tuder; J Wang; C D Cool; R A Lepley; N F Voelkel
Journal:  Am J Respir Crit Care Med       Date:  1998-01       Impact factor: 21.405

9.  In Pulmonary Arterial Hypertension, Reduced BMPR2 Promotes Endothelial-to-Mesenchymal Transition via HMGA1 and Its Target Slug.

Authors:  Rachel K Hopper; Jan-Renier A J Moonen; Isabel Diebold; Aiqin Cao; Christopher J Rhodes; Nancy F Tojais; Jan K Hennigs; Mingxia Gu; Lingli Wang; Marlene Rabinovitch
Journal:  Circulation       Date:  2016-04-04       Impact factor: 29.690

Review 10.  Genetics and genomics of pulmonary arterial hypertension.

Authors:  Nicholas W Morrell; Micheala A Aldred; Wendy K Chung; C Gregory Elliott; William C Nichols; Florent Soubrier; Richard C Trembath; James E Loyd
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

View more
  25 in total

Review 1.  Newer approaches and novel drugs for inhalational therapy for pulmonary arterial hypertension.

Authors:  Ali Keshavarz; Hossam Kadry; Ahmed Alobaida; Fakhrul Ahsan
Journal:  Expert Opin Drug Deliv       Date:  2020-02-19       Impact factor: 6.648

Review 2.  'There and Back Again'-Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension.

Authors:  Emilia M Swietlik; Matina Prapa; Jennifer M Martin; Divya Pandya; Kathryn Auckland; Nicholas W Morrell; Stefan Gräf
Journal:  Genes (Basel)       Date:  2020-11-26       Impact factor: 4.096

Review 3.  Insights on the Gut-Mesentery-Lung Axis in Pulmonary Arterial Hypertension: A Poorly Investigated Crossroad.

Authors:  Suellen Darc Oliveira
Journal:  Arterioscler Thromb Vasc Biol       Date:  2022-03-17       Impact factor: 10.514

Review 4.  The Latest in Animal Models of Pulmonary Hypertension and Right Ventricular Failure.

Authors:  Olivier Boucherat; Vineet Agrawal; Allan Lawrie; Sebastien Bonnet
Journal:  Circ Res       Date:  2022-04-28       Impact factor: 23.213

5.  PPARγ-p53-Mediated Vasculoregenerative Program to Reverse Pulmonary Hypertension.

Authors:  Jan K Hennigs; Aiqin Cao; Caiyun G Li; Minyi Shi; Julia Mienert; Kazuya Miyagawa; Jakob Körbelin; David P Marciano; Pin-I Chen; Matthew Roughley; Matthew V Elliott; Rebecca L Harper; Matthew A Bill; James Chappell; Jan-Renier Moonen; Isabel Diebold; Lingli Wang; Michael P Snyder; Marlene Rabinovitch
Journal:  Circ Res       Date:  2020-12-16       Impact factor: 17.367

6.  Mineralocorticoid receptor antagonist treatment of established pulmonary arterial hypertension improves interventricular dependence in the SU5416-hypoxia rat model.

Authors:  Mengyun Lu; Li-Yuan Chen; Salina Gairhe; Adrien J Mazer; Stasia A Anderson; Jasmine N H Nelson; Audrey Noguchi; Mohammad Abdul Hai Siddique; Edward J Dougherty; Yvette Zou; Kathryn A Johnston; Zu-Xi Yu; Honghui Wang; Shuibang Wang; Junfeng Sun; Steven B Solomon; Rebecca R Vanderpool; Michael A Solomon; Robert L Danner; Jason M Elinoff
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2022-01-19       Impact factor: 5.464

7.  Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances.

Authors:  Bradley A Maron; Steven H Abman; C Greg Elliott; Robert P Frantz; Rachel K Hopper; Evelyn M Horn; Mark R Nicolls; Oksana A Shlobin; Sanjiv J Shah; Gabor Kovacs; Horst Olschewski; Erika B Rosenzweig
Journal:  Am J Respir Crit Care Med       Date:  2021-06-15       Impact factor: 30.528

8.  ALDH1A3 Coordinates Metabolism With Gene Regulation in Pulmonary Arterial Hypertension.

Authors:  Dan Li; Ning-Yi Shao; Jan-Renier Moonen; Zhixin Zhao; Minyi Shi; Shoichiro Otsuki; Lingli Wang; Tiffany Nguyen; Elaine Yan; David P Marciano; Kévin Contrepois; Caiyun G Li; Joseph C Wu; Michael P Snyder; Marlene Rabinovitch
Journal:  Circulation       Date:  2021-03-25       Impact factor: 39.918

9.  Single-cell RNA sequencing reveals that BMPR2 mutation regulates right ventricular function via ID genes.

Authors:  Mingxia Du; Haibin Jiang; Hongxian Liu; Xin Zhao; Yu Zhou; Fang Zhou; Chunmei Piao; Guoqiang Xu; Feng Ma; Jianan Wang; Frederic Perros; Nicholas W Morrell; Hong Gu; Jun Yang
Journal:  Eur Respir J       Date:  2022-07-07       Impact factor: 33.795

Review 10.  Leukotrienes in Tumor-Associated Inflammation.

Authors:  Wen Tian; Xinguo Jiang; Dongeon Kim; Torrey Guan; Mark R Nicolls; Stanley G Rockson
Journal:  Front Pharmacol       Date:  2020-08-19       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.